CurrentCapital BluecrossPolicy MP 2.325

Genetic Cancer Susceptibility Panels Using Next Generation Sequencing

This policy governs coverage and medical necessity determinations for genetic cancer susceptibility multigene panels using next-generation sequencing for Capital BlueCross members; it affects providers ordering hereditary cancer genetic testing and laboratories performing NGS-based panels.

Policy Summary

PayerCapital Bluecross

PolicyGenetic Cancer Susceptibility Panels Using Next Generation Sequencing

Policy CodePolicy MP 2.325

Change TypeNo material change

Effective DateJan 1, 2026

Next Review Date

Key ActionDocument that genetic counseling was provided by an individual with expertise in genetic medicine/testing when ordering genetic testing for an inherited condition.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

~50%VUS rate (large panels)

1%APC-related colorectal cancers (FAP)

60%-80%Lynch syndrome lifetime colon cancer risk

up to 90%TP53 (Li-Fraumeni) lifetime cancer risk

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Position and Rationale

Coverage stance

Policy stance and conditional coverage

Primary rule: General genetic cancer susceptibility panel testing is considered investigational

However, limited genetic cancer susceptibility panels that include only the gene variants for which a member qualifies may be considered medically necessary when the coverage criteria of other, gene-specific policies are met (see related policies).

Investigational / Not covered as standard

Overall policy position and summary of evidence

Policy stance: Genetic cancer susceptibility panels using next-generation sequencing are considered investigational due to insufficient evidence of clinical utility and potential harms from high rates of variants of uncertain significance.~50% VUS rate for large panels

Evidence reports diagnostic yield and variant frequency but lacks data demonstrating improvement in net health outcome; many panels include moderate- or low-penetrance genes with unclear management pathways, increasing potential for harm.

The policy states that general genetic cancer susceptibility panel testing is considered investigational. However, it allows that limited panels that include only the gene variants for which a member meets the coverage criteria of other, gene‑specific policies may be considered medically necessary when those referenced policy criteria are satisfied.

Many expanded panels include genes and variants with moderate or low penetrance and report a substantial number of variants of uncertain significance (VUS). The document highlights that VUS rates increase with panel size and that the resulting uncertain results often lack defined clinical management pathways, limiting the utility of such findings for patient care.

Panel testing using next‑generation sequencing assesses multiple genes simultaneously and can detect more variants than targeted single‑gene testing, but the policy explains that broad or unselected use of such panels is problematic. Expanded, unfocused panels commonly return results (including VUS and low/moderate penetrance variants) that do not have clear implications for management, and therefore the routine use of broad panels in unselected populations is considered investigational.

The summary of evidence indicates that published data on clinical utility are lacking: studies primarily report diagnostic yield and variant frequencies rather than improved health outcomes. It is unknown whether expanded panels improve net health outcomes, and the evidence is insufficient to conclude they provide clinical benefit over targeted testing.

When Limited Panels May Be Covered

Limited panels that include only the gene variants for which a member qualifies according to the coverage criteria of other, gene-specific policies

Covered when ALL of the following are met:

Limited panel requirement: The panel includes only the gene variants for which the member qualifies according to the coverage criteria of other, gene-specific Capital BlueCross policies.

See cross-referenced gene-specific policies (e.g., BRCA, Lynch, Li-Fraumeni) to establish medical necessity for testing those genes.

Individuals with personal and/or family history suggesting an inherited cancer syndrome

Clinical context for consideration

Population: Individual has a personal and/or family history suggesting an inherited cancer syndrome.

Although this describes the clinical population in which testing may be considered, evidence is insufficient to support expanded multigene panels for improving health outcomes; management pathways for many variants are not well-defined and VUS rates are high.

Eligibility and Testing Preconditions

No top‑level eligibility requirement nodes are specified in this policy.

Tests and Situations Considered Not Medically Necessary

Unfocused, expanded genetic cancer susceptibility panels that test many genes without meeting targeted, gene‑specific criteria are explicitly listed as investigational and not covered. The policy advises that such panels are discouraged unless testing is limited to genes for which the member meets the criteria of other referenced policies.

The policy specifies that genetic cancer susceptibility panels using next‑generation sequencing are considered investigational and may be denied; the coding information clarifies that listing a CPT/PLA code does not imply coverage and that these NGS‑based expanded panels are not covered under the policy stance.

Relevant Procedure and Billing Codes

Codes referenced for genetic cancer susceptibility panelsmixed

0475U	Procedure code referenced for panels
81437	CPT/HCPCS code mapping listed in policy
81445	CPT/HCPCS code mapping listed in policy
81449	CPT/HCPCS code mapping listed in policy
81450	CPT/HCPCS code mapping listed in policy
81451	CPT/HCPCS code mapping listed in policy
81455	CPT/HCPCS code mapping listed in policy
81456	CPT/HCPCS code mapping listed in policy
0129U	Previously referenced PLA/procedure code (see history for additions/removals)
0329U	Previously added code (history notes)

1–10 of 11

1/2

Notesmixed

No codes listed

VUS rate for large gene panels (inv-08)

Approximate VUS rate for large gene panelsVariants of uncertain significance (VUS) increase with panel size and reach nearly 50% for large gene panels.

Impact on clinical utilityHigh VUS rates contribute to lack of demonstrated clinical utility and increase potential for harm due to uncertain management pathways.

Relation to panel sizeThe rate of VUS rises in proportion to panel size — larger NGS panels have the highest VUS proportions.

Provider Requirements, Documentation, and Ordering Notes

Prior Authorization

Prior Authorization and Product Variations

Prior authorization requirement varies by product and program. Providers must follow product-specific prior authorization rules and the member’s benefit program. Refer to product benefit variations and applicable policies (see Cross-References) and contact Capital Blue Cross prior authorization services when required.

Verify whether prior authorization is required for the specific product/program before ordering testing.
Follow product/program-specific ordering rules and the applicable related genetic testing policies listed in Cross-References (chunk 6).

Billing Rule

Coding Listed Does Not Equal Coverage

Coding listed in the policy or in the coding section does not by itself indicate coverage. Claims adjudication depends on the member’s specific benefits and medical necessity determination. Providers should not assume that an identified code guarantees payment.

Key Terms and Laboratory Definitions

Variant classification (ACMG-AMP) — standard terms (inv-18)

Standard variant terminology (ACMG-AMP)Pathogenic; Likely pathogenic; Variant of uncertain significance (VUS); Likely benign; Benign — per ACMG-AMP/CAP guidance.

Nomenclature sourceACMG-AMP standards and the Human Genome Variation Society nomenclature are used as the recommended terminology for reporting variants.

Scope of applicationTerminology applies to variants identified in genotyping, single genes, panels, exomes, and genomes in clinical laboratories.

Laboratory-developed test (LDT) definition and CLIA requirement (inv-19)

Definition of LDTA laboratory-developed test (LDT) is a test developed and validated in-house by a clinical laboratory and marketed as a laboratory service.

CLIA requirement

Context and Policy Scope

Genetic testing for cancer susceptibility can be performed by targeted single‑gene testing when clinical suspicion indicates a specific gene, or by multigene panel testing using NGS when multiple genes are considered. The policy emphasizes that while NGS panels can increase detection of variants, they also increase the rate of VUS and may identify variants without established management guidelines, supporting a preference for focused testing when appropriate.